Diphemanil

Summary

Diphemanil (CHEMBL1201340) is an approved small molecule (ATC A03AB15); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03AB15
• Indications: 1 condition
• Chemistry: 278.4 Da · C20H24N+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201340
Name	Diphemanil
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6127
ATC	A03AB15
Molecular formula	C20H24N+
Molecular weight	278.4
InChIKey	LCTZPQRFOZKZNK-UHFFFAOYSA-N

SMILES: C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C

IUPAC name: 4-benzhydrylidene-1,1-dimethylpiperidin-1-ium

Also known as: Diphemanil, Diphemanil cation, Diphemanil ion, SID11112168, DIPHEMANIL, Diphemanil Methylsulfate, diphemanil

Parent form; salt/anhydrous children: CHEMBL1200880

Patent coverage: 7 distinct patent families (9 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Prelamin-A/C, 5-hydroxytryptamine receptor 2B, Neuronal acetylcholine receptor subunit alpha-4, 5-hydroxytryptamine receptor 3A, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, 5-hydroxytryptamine receptor 2A, Histamine H1 receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 14 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM1	6.92	AC50	120	nM	CHEMBL_ACT_25210765
CHRM2	6.8	AC50	160	nM	CHEMBL_ACT_25213431
CHRM2	6.78	AC50	166.8	nM	CHEMBL_ACT_25195188
KCNH2	6.73	AC50	187	nM	CHEMBL_ACT_25117381
CHRM3	6.72	AC50	190	nM	CHEMBL_ACT_25136382
CHRM1	6.39	AC50	410	nM	CHEMBL_ACT_25135124
HRH1	5.54	AC50	2900	nM	CHEMBL_ACT_25212183
HTR3A	5.21	AC50	6100	nM	CHEMBL_ACT_25148808

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).